- Home
- MNMD vs SDHY Comparison
MNMD vs SDHY Comparison
Compare MNMD & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- SDHY
- Stock Information
- Founded
- MNMD 2019
- SDHY 2020
- Country
- MNMD United States
- SDHY United States
- Employees
- MNMD N/A
- SDHY N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- SDHY Finance/Investors Services
- Sector
- MNMD Health Care
- SDHY Finance
- Exchange
- MNMD Nasdaq
- SDHY Nasdaq
- Market Cap
- MNMD 509.2M
- SDHY 411.1M
- IPO Year
- MNMD N/A
- SDHY N/A
- Fundamental
- Price
- MNMD $9.61
- SDHY $16.76
- Analyst Decision
- MNMD Strong Buy
- SDHY
- Analyst Count
- MNMD 7
- SDHY 0
- Target Price
- MNMD $24.71
- SDHY N/A
- AVG Volume (30 Days)
- MNMD 1.3M
- SDHY 94.0K
- Earning Date
- MNMD 07-31-2025
- SDHY 01-01-0001
- Dividend Yield
- MNMD N/A
- SDHY 8.46%
- EPS Growth
- MNMD N/A
- SDHY N/A
- EPS
- MNMD N/A
- SDHY 1.07
- Revenue
- MNMD N/A
- SDHY N/A
- Revenue This Year
- MNMD N/A
- SDHY N/A
- Revenue Next Year
- MNMD N/A
- SDHY N/A
- P/E Ratio
- MNMD N/A
- SDHY $14.31
- Revenue Growth
- MNMD N/A
- SDHY N/A
- 52 Week Low
- MNMD $4.70
- SDHY $13.93
- 52 Week High
- MNMD $10.49
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- MNMD 56.17
- SDHY 53.31
- Support Level
- MNMD $7.96
- SDHY $16.67
- Resistance Level
- MNMD $10.49
- SDHY $17.01
- Average True Range (ATR)
- MNMD 0.55
- SDHY 0.10
- MACD
- MNMD -0.06
- SDHY 0.01
- Stochastic Oscillator
- MNMD 65.22
- SDHY 42.05
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.